Systematic Financial Management LP Boosts Stock Holdings in Biogen Inc. $BIIB

Systematic Financial Management LP grew its position in shares of Biogen Inc. (NASDAQ:BIIB) by 256.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 16,640 shares of the biotechnology company’s stock after buying an additional 11,970 shares during the quarter. Systematic Financial Management LP’s holdings in Biogen were worth $2,928,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in the company. Advisory Services Network LLC boosted its holdings in Biogen by 3.9% in the third quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock worth $251,000 after purchasing an additional 68 shares during the last quarter. Davis Investment Partners LLC boosted its holdings in Biogen by 1.7% in the fourth quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock worth $778,000 after purchasing an additional 71 shares during the last quarter. Optas LLC boosted its holdings in Biogen by 4.5% in the fourth quarter. Optas LLC now owns 1,706 shares of the biotechnology company’s stock worth $300,000 after purchasing an additional 73 shares during the last quarter. CIBC Private Wealth Group LLC boosted its holdings in Biogen by 8.1% in the third quarter. CIBC Private Wealth Group LLC now owns 1,189 shares of the biotechnology company’s stock worth $167,000 after purchasing an additional 89 shares during the last quarter. Finally, Parkside Financial Bank & Trust boosted its holdings in Biogen by 5.6% in the third quarter. Parkside Financial Bank & Trust now owns 1,739 shares of the biotechnology company’s stock worth $244,000 after purchasing an additional 92 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on BIIB. Wolfe Research set a $231.00 target price on shares of Biogen in a report on Monday, February 9th. Wells Fargo & Company increased their price target on shares of Biogen from $190.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Sunday, February 8th. UBS Group upgraded shares of Biogen from a “neutral” rating to a “buy” rating and increased their price target for the stock from $185.00 to $225.00 in a research report on Wednesday, April 22nd. Guggenheim increased their price target on shares of Biogen from $246.00 to $260.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Finally, Rothschild & Co Redburn increased their price target on shares of Biogen from $180.00 to $190.00 in a research report on Thursday, April 30th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $215.62.

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen’s stock may be getting some support from analyst commentary suggesting the recent sell-off could be overdone, with one report saying the trial results were better than first reported and that longer-term optimism remains intact. Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish
• Neutral Sentiment: Denali said it will keep running a separate Phase 2a BEACON study in carriers of a pathogenic LRRK2 variant, which preserves some optionality for the broader program but does not offset the failure in idiopathic Parkinson’s disease. Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
• Negative Sentiment: The failed Parkinson’s trial has also sparked investor concern and legal scrutiny, with multiple alerts and investigations following the disclosure, adding another overhang to Biogen shares. Investor Alert: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. – BIIB

Biogen Price Performance

BIIB opened at $193.76 on Monday. The company has a market capitalization of $28.61 billion, a PE ratio of 20.79, a PEG ratio of 1.71 and a beta of 0.19. Biogen Inc. has a 1-year low of $121.05 and a 1-year high of $205.97. The firm’s 50 day simple moving average is $185.48 and its two-hundred day simple moving average is $180.95. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, beating the consensus estimate of $2.95 by $0.62. The firm had revenue of $2.48 billion for the quarter, compared to the consensus estimate of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The company’s revenue was up 1.9% on a year-over-year basis. During the same period last year, the firm earned $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, equities analysts forecast that Biogen Inc. will post 14.18 EPS for the current year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.